Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

Fabian Acker, Lukas Aguinarte, Friederike Althoff, Sophie Heinzen, Maximilian Rost, Peter J. Wild, Lena Reiser, Martin Mänz, Frauke Meyer, Jan Stratmann, Martin Sebastian